XML 28 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Note 11 - Accrued Expenses
 6 Months Ended
Jun. 30, 2018
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
11.
Accrued Expenses
 
Accrued expenses consist of the following:
 
    June 30,
2018		   December 31,
2017
Compensation and related expenses   $
3,633
     $
2,893
  
Clinical trial costs    
867
      
2,318
  
Accrued liabilities related to product recall    
1181
      
-
  
Research grants    
408
      
419
  
Professional fees    
1,213
      
448
  
Deferred income    
74
      
-
  
Other    
83
      
248
  
Total   $
7,459
     $
6,326
  
 
Included in Compensation and related expenses as of
June 30, 2018
are the accrued and unpaid costs related to the retirement of the Company’s former Chief Executive Officer as of
March 9, 2018.
Under the terms of his employment agreement, the former Chief Executive Officer is entitled to receive from the Company, as a result of his retirement, aggregate benefits of
$1.7
million over the
18
-month period subsequent to
March 9, 2018,
among other benefits. On
March 8, 2018
the Company entered into a
$0.3
million
one
-year, post-retirement consulting agreement with the former Chief Executive Officer to provide certain services as
may
be requested by the Company through
February 28, 2019.
The unpaid amounts under these agreements are included in accrued expenses and other long-term liabilities. As more fully described in Note
6,
all of the former Chief Executive Officer’s outstanding equity awards vested in full and became exercisable upon his retirement.
 
Accrued liabilities related to product recall includes amounts due to customers for estimated product returns as a result of the voluntary recall more fully described in Note
3
as well as an accrual of
$0.4
million for future expenses associated with the administration and remediation of the voluntary recall.